icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NA¤VE GENOTYPE 1-4 PATIENTS
 
 
  Reported by Jules Levin
EASL 2016 Barcelona April 14-17
 
Elina Berliba1,Tengiz Tsertsvadze2, Nelea Ghicavii3, Dominique Guyader4, Tea Kakabadze5, Christopher Westland6,Sushmita Chanda7, Alain Patat8, Qingling Zhang7, David B. Smith9, Jeysen Yogaratnam6, Matthew W. McClure6, Leo Beigelman9, Lawrence M. Blatt6, John Fry6 1Internal Medicine, State Medical University "N. Testemitanu", Chisinau, Moldova, Republic of, 2Director General, AIDS and Clinical Immunology Research Center of Georgia, Tbilisi, Georgia,
3ARENSIA Exploratory Medicine Phase 1 Unit, ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of, 4CHU de Rennes, University of Rennes, Rennes, France, 5ARENSIA Exploratory Medicine Phase 1 Unit, ARENSIA Exploratory Medicine, Tbilisi, Georgia, 6Clinical Development, 7Preclinical , Alios BioPharma, South San Francisco, United States, 8Regulatory Affairs, Biotrial, Rennes, France, 9Early Development, Alios BioPharma, South San Francisco, United States

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8